GB Sciences, Inc. (GBLX) Research

Operating across North America and Europe, GB Sciences, Inc. is dedicated to the research and development of plant-based pharmaceuticals. The company specializes in crafting cannabinoid-inspired medications and complex therapeutic formulations intended for the prescription drug market. Its extensive intellectual property portfolio addresses a variety of medical conditions, with programs currently in pre-clinical animal stages. These include initiatives for Parkinson's disease, neuropathic and chronic pain, COVID-related cytokine release syndrome, depression/anxiety, and cardiovascular ailments. Formed in 2001 and headquartered in Las Vegas, Nevada, the company was formerly known as Growblox Sciences, Inc. before rebranding in October 2016.

Market snapshot

Symbol
GBLX
Price
$0.00
Day change
0.00%
Market cap
$122.1K
P/E ratio
-0.09x
52-week range
0.0001-0.50015
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Acusphere, Inc. (ACUS)
  • Bioasis Technologies Inc. (BIOAF)
  • Ehouse Global, Inc. (EHOS)
  • GlobeStar Therapeutics Corporation (GSTC)
  • Hard to Treat Diseases Inc. (HTDS)
  • IR Biosciences Holdings Inc. (IRBS)
  • Mobile Lads Corp. (MOBO)
  • Panbela Therapeutics, Inc. (PBLA)

Recent insider activity

  • POSS JOHN C — P-Purchase (3615 shares) on 2018-07-11
  • POSS JOHN C — P-Purchase (11915 shares) on 2018-07-11
  • POSS JOHN C — P-Purchase (20000 shares) on 2018-07-11
  • POSS JOHN C — P-Purchase (1250 shares) on 2018-07-11
  • POSS JOHN C — P-Purchase (30000 shares) on 2018-07-11

Open GB Sciences, Inc. (GBLX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.